Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H26N2O5 |
| Molecular Weight | 398.4522 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCC1=CC=C(C=C1)C2=CC3=CN([C@H]4C[C@H](O)[C@@H](CO)O4)C(=O)N=C3O2
InChI
InChIKey=MFGSDSRTGUVZQG-DFQSSKMNSA-N
InChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
Valnivudine, also known as FV-100, a prodrug that has been indicated as a potential antiviral for the treatment of shingles (herpes zoster) that could both reduce the pain burden of the acute episode and reduce the incidence of post‐herpetic neuralgia compared to available treatments. Phase I clinical trial with FV100 showed safety and tolerability in healthy volunteers. Valnivudine also participated in phase III, where its efficacy was compared with valacyclovir; however, the study was terminated.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. | 2000 Dec 28 |
|
| Novel aryl substituted bicyclic furo nucleosides as extremely potent and selective anti-VZV agents. | 2001 Apr-Jul |
|
| FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. | 2017 Jul |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
319425-66-6
Created by
admin on Sat Dec 16 04:37:25 GMT 2023 , Edited by admin on Sat Dec 16 04:37:25 GMT 2023
|
PRIMARY | |||
|
493485
Created by
admin on Sat Dec 16 04:37:25 GMT 2023 , Edited by admin on Sat Dec 16 04:37:25 GMT 2023
|
PRIMARY | |||
|
5XGI48Q2DH
Created by
admin on Sat Dec 16 04:37:25 GMT 2023 , Edited by admin on Sat Dec 16 04:37:25 GMT 2023
|
PRIMARY | |||
|
DTXSID60185781
Created by
admin on Sat Dec 16 04:37:25 GMT 2023 , Edited by admin on Sat Dec 16 04:37:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
